Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Next Previous
Trial Profile

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamitresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Myxoid liposarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SPEARHEAD-1
  • Sponsors Adaptimmune

Most Recent Events

  • 13 Nov 2024 According to an Adaptimmune media release, the SITC presentation of this trial will also be repeated at CTOS 2024 annual meeting, on Saturday, November 16 10:30 AM - 12:00 PM PST, Session 12: Immunology.
  • 13 Nov 2024 According to an Adaptimmune media release, translational data from this trial was presented at the Society for Immunotherapy of Cancer (SITC) 39th annual meeting by Mihaela Druta, MD, Vice Chair, Sarcoma Center, Moffitt Cancer Center, on November 8.
  • 13 Nov 2024 According to an Adaptimmune media release, Tecelra launch is on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient has been apheresed in Q3.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top